The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy

Takeshi Tomoda, Toru Ueki, Syunsuke Saito, Tomoo Fujisawa, Toru Nawa, Hiromi Hamamoto, Hisashi Endo, Kazuhisa Yabushita, Toshinari Shimoe, Kosaku Sakaguchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7%) and 6 patients (2.5%), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7%) and 2 patients (4.4%), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9%) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.

Original languageEnglish
Pages (from-to)2150-2155
Number of pages6
JournalGastroenterological Endoscopy
Volume56
Issue number7
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Endoscopic Sphincterotomy
Safety
Platelet Aggregation Inhibitors
Hemorrhage
Anticoagulants
Therapeutics
Guidelines
Thromboembolism
Aspirin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Tomoda, T., Ueki, T., Saito, S., Fujisawa, T., Nawa, T., Hamamoto, H., ... Sakaguchi, K. (2014). The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy. Gastroenterological Endoscopy, 56(7), 2150-2155.

The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy. / Tomoda, Takeshi; Ueki, Toru; Saito, Syunsuke; Fujisawa, Tomoo; Nawa, Toru; Hamamoto, Hiromi; Endo, Hisashi; Yabushita, Kazuhisa; Shimoe, Toshinari; Sakaguchi, Kosaku.

In: Gastroenterological Endoscopy, Vol. 56, No. 7, 01.01.2014, p. 2150-2155.

Research output: Contribution to journalArticle

Tomoda, T, Ueki, T, Saito, S, Fujisawa, T, Nawa, T, Hamamoto, H, Endo, H, Yabushita, K, Shimoe, T & Sakaguchi, K 2014, 'The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy', Gastroenterological Endoscopy, vol. 56, no. 7, pp. 2150-2155.
Tomoda T, Ueki T, Saito S, Fujisawa T, Nawa T, Hamamoto H et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy. Gastroenterological Endoscopy. 2014 Jan 1;56(7):2150-2155.
Tomoda, Takeshi ; Ueki, Toru ; Saito, Syunsuke ; Fujisawa, Tomoo ; Nawa, Toru ; Hamamoto, Hiromi ; Endo, Hisashi ; Yabushita, Kazuhisa ; Shimoe, Toshinari ; Sakaguchi, Kosaku. / The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy. In: Gastroenterological Endoscopy. 2014 ; Vol. 56, No. 7. pp. 2150-2155.
@article{88af960e2f71477c9228cbf4e7eaf277,
title = "The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy",
abstract = "Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7{\%}) and 6 patients (2.5{\%}), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7{\%}) and 2 patients (4.4{\%}), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9{\%}) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.",
author = "Takeshi Tomoda and Toru Ueki and Syunsuke Saito and Tomoo Fujisawa and Toru Nawa and Hiromi Hamamoto and Hisashi Endo and Kazuhisa Yabushita and Toshinari Shimoe and Kosaku Sakaguchi",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "56",
pages = "2150--2155",
journal = "Gastroenterological Endoscopy",
issn = "0387-1207",
publisher = "Japan Gastroenterological Endoscopy Society",
number = "7",

}

TY - JOUR

T1 - The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy

AU - Tomoda, Takeshi

AU - Ueki, Toru

AU - Saito, Syunsuke

AU - Fujisawa, Tomoo

AU - Nawa, Toru

AU - Hamamoto, Hiromi

AU - Endo, Hisashi

AU - Yabushita, Kazuhisa

AU - Shimoe, Toshinari

AU - Sakaguchi, Kosaku

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7%) and 6 patients (2.5%), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7%) and 2 patients (4.4%), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9%) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.

AB - Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7%) and 6 patients (2.5%), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7%) and 2 patients (4.4%), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9%) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.

UR - http://www.scopus.com/inward/record.url?scp=84938067462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938067462&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84938067462

VL - 56

SP - 2150

EP - 2155

JO - Gastroenterological Endoscopy

JF - Gastroenterological Endoscopy

SN - 0387-1207

IS - 7

ER -